As of March 20, 2023, around 391 doses of COVID-19 vaccines per 100 people in Cuba had been administered, one of the highest COVID-19 vaccine dose rates of any country worldwide. This statistic shows the rate of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country or territory.

Based on a comparison of coronavirus deaths in 210 countries relative to their population, Peru had the most losses to COVID-19 up until July 13, 2022. As of the same date, the virus had infected over 557.8 million people worldwide, and the number of deaths had totaled more than 6.3 million. Note, however, that COVID-19 test rates can vary per country. Additionally, big differences show up between countries when combining the number of deaths against confirmed COVID-19 cases. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

The difficulties of death figures

This table aims to provide a complete picture on the topic, but it very much relies on data that has become more difficult to compare. As the coronavirus pandemic developed across the world, countries already used different methods to count fatalities, and they sometimes changed them during the course of the pandemic. On April 16, for example, the Chinese city of Wuhan added a 50 percent increase in their death figures to account for community deaths. These deaths occurred outside of hospitals and went unaccounted for so far. The state of New York did something similar two days before, revising their figures with 3,700 new deaths as they started to include “assumed” coronavirus victims. The United Kingdom started counting deaths in care homes and private households on April 29, adjusting their number with about 5,000 new deaths (which were corrected lowered again by the same amount on August 18). This makes an already difficult comparison even more difficult. Belgium, for example, counts suspected coronavirus deaths in their figures, whereas other countries have not done that (yet). This means two things. First, it could have a big impact on both current as well as future figures. On April 16 already, UK health experts stated that if their numbers were corrected for community deaths like in Wuhan, the UK number would change from 205 to “above 300”. This is exactly what happened two weeks later. Second, it is difficult to pinpoint exactly which countries already have “revised” numbers (like Belgium, Wuhan or New York) and which ones do not. One work-around could be to look at (freely accessible) timelines that track the reported daily increase of deaths in certain countries. Several of these are available on our platform, such as for Belgium, Italy and Sweden. A sudden large increase might be an indicator that the domestic sources changed their methodology.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

Vaccine program plays a vital role in building herd immunity in the worldwide population during the spread of the COVID-19 pandemic. This study aimed to identify the key factors affecting vaccination intention against COVID-19 using a new three-staged approach combining both Spherical Fuzzy Analytic Hierarchy Process (SF-AHP), Structural Equation Model (SEM), and Artificial Neural Network (ANN) to determine the relative weight and importance of the factors as well as to test the proposed hypotheses in the research model. Using online survey questionnaires, data were collected from 474 respondents throughout Vietnam. The findings of SF-AHP demonstrated that Perceived COVID-19 vaccines (PVC), Trust in government intervention strategies (TRS), and Social media (SOM) were the most important factors predicting vaccination intention against COVID-19 pandemic, based on fifteen experts’ points of view. The results of the SEM showed that individuals’ vaccination intention was significantly and directly influenced by Perceived COVID-19 vaccines (PVC), Trust in government intervention strategies (TRS). Although Perceived severity of COVID-19 (PSC) did not perform a direct influence on vaccination intention, its indirect influence through Perceived COVID-19 vaccines (PVC), and Social media (SOM) had no direct effect on the intention to receive COVID-19 vaccines, however, indirectly affecting COVID-19 vaccination intention moderating through trust in government strategy. However, Social Influence (SOI) was found no have a significant direct effect on the intention to take a vaccine against COVID-19. Finally, the ANNs’ findings were consistent with the SF-AHP and SEM models, also revealed that the best predictors of COVID-19 vaccination intention were Perceived COVID-19 vaccines (PVC), Trust in government intervention strategies (TRS), and Social media (SOM). The ANN model can predict vaccination intention with an accuracy of 90 %. This research proposed an innovative new approach employing quantitative and qualitative techniques to understand COVID-19 vaccination intention during the global pandemic. Furthermore, the proposed method can be applied and extended to evaluate the perceived effectiveness of COVID-19 measures in other countries currently dealing with the COVID-19 outbreak.

Descriptive statistics for the new death, new cases and vaccine doses (n = 435).

Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic that has affected millions of people worldwide. This study aims to bridge the knowledge gap between acute and chronic symptoms, vaccination impact, and associated factors in patients across different low-income countries.Methods: The study included 2,445 participants aged 18 years and older, testing positive for COVID-19. Data collection involved screening for medical histories, testing records, symptomatology, and persistent symptoms. Validated instruments, including the DePaul Symptom Questionnaire (DSQ-2) and Patient Health Questionnaire-9 (PHQ-9), were used. We applied a self-supervised and unsupervised deep neural network to extract features from the questionnaire. Gradient boosted machines (GMB) model was used to build a risk calculator for chronic fatigue, depression, and prolonged COVID-19 symptoms. The best-performing models were implemented in a shiny app and deployed online at: [https//ahmedshaheen.shinyapps.io/shaheen-covid-19/]. Also, there is an offline version of the application that can be downloaded: [link].Findings: Out of the study cohort, 69.5% of the patients had symptoms lasting longer than 2 weeks. The most frequent symptoms were loss of smell 46.8%, dry cough (40.1%), loss of taste (37.8%), headaches (37.2%), and sore throat (28.9%). The patients also reported high rates of depression (47.7%), chronic fatigue (6.5%), and infection after vaccination (24.2%). Factors associated with chronic fatigue syndrome included sex, age, and smoking. Vaccinated individuals demonstrated lower odds of experiencing prolonged COVID-19 symptoms, chronic fatigue syndrome, and depression. The predictive models achieved a high area under the receiver operating characteristic curve (AUC) scores of 0.87, 0.82, and 0.74, respectively.Interpretation: The results provide insights into the consequences of COVID-19 and a predictive tool to understand factors influencing depression, chronic fatigue syndrome, and prolonged COVID-19 symptoms. The study reveals variables affecting these outcomes and the interplay between pre-existing conditions, treatments, and the duration of symptoms post-recovery.

As of November 14, 2021, all S&P 500 sector indices had recovered to levels above those of January 2020, prior to full economic effects of the global coronavirus (COVID-19) pandemic taking hold. However, different sectors recovered at different rates to sit at widely different levels above their pre-pandemic levels. This suggests that the effect of the coronavirus on financial markets in the United States is directly affected by how the virus has impacted various parts of the underlying economy. Which industry performed the best during the coronavirus pandemic? Companies operating in the information technology (IT) sector have been the clear winners from the pandemic, with the IT S&P 500 sector index sitting at almost ** percent above early 2020 levels as of November 2021. This is perhaps not surprising given this industry includes some of the companies who benefitted the most from the pandemic such as ************** and *******. The reason for these companies’ success is clear – as shops were shuttered and social gatherings heavily restricted due to the pandemic, online services such shopping and video streaming were in high demand. The success of the IT sector is also reflected in the performance of global share markets during the coronavirus pandemic, with tech-heavy NASDAQ being the best performing major market worldwide. Which industry performed the worst during the pandemic? Conversely, energy companies fared the worst during the pandemic, with the S&P 500 sector index value sitting below its early 2020 value as late as July 2021. Since then it has somewhat recovered, and was around ** percent above January 2020 levels as of October 2021. This reflects the fact that many oil companies were among the share prices suffering the largest declines over 2020. A primary driver for this was falling demand for fuel in line with the reduction in tourism and commuting caused by lockdowns all over the world. However, as increasing COVID-19 vaccination rates throughout 2021 led to lockdowns being lifted and global tourism reopening, demand has again risen - reflected by the recent increase in the S&P 500 energy index.

ANOVA results for new death, new cases, and vaccine doses.

The graph depicts Pfizer's top 10 products based on revenue in 2024. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2024, Pfizer's top product was Eliquis. COVID-19 vaccine Comirnaty, on the other hand, showed another dramatic decline in sales from **** billion U.S. dollars in 2023 to *** billion dollars. Pfizer's top productsPfizer is a pharmaceutical corporation headquartered in New York City, United States. It was founded in **** by Charles Pfizer and Charles Erhart in Brooklyn, New York, where they produced an antiparasitic called santonin. Today, Pfizer produces pharmaceutical products for a wide range of medical sectors that include but are not limited to immunology, cardiology, and neurology. In 2024, Pfizer generated a total revenue of **** billion U.S. dollars worldwide, with oncology products accumulating some **** billion U.S. dollars.Some of Pfizer’s well-known products - although with expired patent protection - include Lyrica and Lipitor, which generated around *** and * billion U.S. dollars in revenue, respectively, in 2019. Pregabalin, marketed as Lyrica, is an anticonvulsant drug used to treat disorders such as epilepsy, diabetic peripheral neuropathy, and fibromyalgia. Lipitor, one of Pfizer’s more well-known products, generated revenues of **** billion U.S. dollars in 2006, however, after Pfizer’s patent on Lipitor expired in 2011, revenue has fallen to under * billion U.S. dollars. Currently, generic forms of atorvastatin (Lipitor) are available. Lipitor is a statin that is used to lower blood cholesterol and to prevent cardiovascular diseases.

Unlike in the two years before, COVID-19 vaccine Comirnaty did not maintain its place as the global top ranked pharmaceutical product based on revenue. Merck's cancer drug Keytruda is the new best-selling drug worldwide, with some 25 billion U.S. dollars of revenue. Humira came in as third ranked drug in 2023, with revenues totaling 14.4 billion dollars.

Humira Humira is used mostly for the treatment of rheumatoid and psoriatic arthritis. However, like many other top drugs, the range of medical conditions it can be used to treat is much larger. Thus, the drug is also used to treat Crohn’s disease, ankylosing spondylitis, ulcerative colitis, psoriasis, uveitis, and some other autoimmune diseases. Humira is administered subcutaneously via injection. It was approved for the first time in 2002 in the United States.

Blockbuster drug reliance Blockbuster drugs often have a large impact on the manufacturer. In some cases, pharmaceutical companies are highly dependent on their sales performance. In the case of Humira, AbbVie generates over 36 percent of its total revenue from this drug and over 53 percent from its top three products. Companies that depend on a small number of blockbuster drugs could be under threat of heavy revenue loss. Biosimilars of Humira (adalimumab) are already available and will take more and more of the market in the years to come. However, Humira has exceeded the 20 billion-dollar-revenue mark in contrast to some predictions made years ago.

Background: Vaccines have been contributing to eradicate or drastically reduce the incidence of common diseases. Simultaneously, vaccine hesitancy is considered among the top ten global health threats. The COVID-19 pandemic has caused a tremendous impact on health, economics, and society worldwide, while also reinforcing faulty beliefs about the necessity of vaccine programs as a whole. This study aims to synthesise evidence on the impact of the COVID-19 pandemic on vaccine hesitancy.Methods: A scoping review of literature between 1 January 2020 and 1 August 2021 was performed.Results: COVID-19 vaccine acceptance decreased from more than 70 to

Residual statistics test for new death, new cases, and vaccine doses.

Brazil is the Latin American country affected the most by the COVID-19 pandemic. As of May 2025, the country had reported around 38 million cases. It was followed by Argentina, with approximately ten million confirmed cases of COVID-19. In total, the region had registered more than 83 million diagnosed patients, as well as a growing number of fatal COVID-19 cases. The research marathon Normally, the development of vaccines takes years of research and testing until options are available to the general public. However, with an alarming and threatening situation as that of the COVID-19 pandemic, scientists quickly got on board in a vaccine marathon to develop a safe and effective way to prevent and control the spread of the virus in record time. Over two years after the first cases were reported, the world had around 1,521 drugs and vaccines targeting the COVID-19 disease. As of June 2022, a total of 39 candidates were already launched and countries all over the world had started negotiations and acquisition of the vaccine, along with immunization campaigns. COVID vaccination rates in Latin America As immunization against the spread of the disease continues to progress, regional disparities in vaccination coverage persist. While Brazil, Argentina, and Mexico were among the Latin American nations with the most COVID-19 cases, those that administered the highest number of COVID-19 doses per 100 population are Cuba, Chile, and Peru. Leading the vaccination coverage in the region is the Caribbean nation, with more than 406 COVID-19 vaccines administered per every 100 inhabitants as of January 5, 2024.For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

In the fiscal year of 2021, Siemens generated over nine billion euros in revenue from its Mobility segment, which comprises all Siemens businesses in passenger and freight transportation. The German engineering and electronics company's best-performing segment for the financial year was its Healthineers segment, with a revenue of almost 18 billion euros. The Digital Industries segment, which is the backbone of Siemens’ portfolio of industrial automation products and solutions, generated almost 17 billions euros in revenue.

Leader of industrial automation Due to Siemens being one of the largest conglomerates in the world with a significant pool of resources, it afford to finance research of various automation technologies that would be too resource-demanding for smaller companies. Just in 2020, Siemens spent around 4.6 billion euros on research and development. Although most of the industrial automation market is dominated by big conglomerates, there is still room for smaller companies and start-ups to thrive. As more industries want to automate, the growing market offers opportunities for companies that can come up with innovate products and solutions.

Digitalization of vaccine development
In 2021, Siemens started collaborating with a pharmaceutical company GSK to digitalize the process of vaccine development and production process. Working together with ATOS, a consulting company in the field of IT, Siemens will use data from a real plant in which vaccines are developed and produced to create its digital twin. In this digital twin, simulations of vaccine development and production will be run, saving GSK hours of real-life work and speeding up the development and production of vaccines.
GSK is currently collaborating with the French pharmaceuticals company Sanofi to develop a Covid-19 vaccine. While still in a phase three clinical trial as of May 2021, the companies have received more than 700 million orders for the vaccine.

Collinearity diagnostics test for new death, new cases and vaccine doses.

Correlation coefficients result for new death, new cases, and vaccine doses.

Johnson and Johnson is a leading international pharmaceutical company. In 2024, among its top pharmaceutical products was Darzalex which earned some **** billion U.S. dollars of revenue. Darzalex is a drug used in the treatment of multiple myeloma and light chain amyloidosis. International pharmaceutical companies There are several major pharmaceutical companies that are making significant economic impacts globally. In 2023, Johnson & Johnson, AbbVie, and Novartis were the top pharmaceutical companies based on their prescription drug sales globally. When viewed by market capitalization, Johnson and Johnson was the third ranked global pharmaceutical company, as of 2024. Top pharmaceuticals The global pharmaceutical industry showed significant growth of revenues over the past two decades. Globally, oncology, diabetes and immunology are considered the top therapeutic areas for future growth. In 2023, when covid vaccines are excluded, Humira by AbbVie, Keytruda by Merck & Co. and Ozempic by Novo Nordisk were the top drugs based on sales worldwide.

Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2024, the company's total revenue stood at **** billion U.S. dollars. Pfizer’s global positioning Pfizer’s products are available in many countries worldwide and as of 2024, the company had more than *** research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few. Pfizer’s top products In 2024, products from the Prevnar family were among Pfizer's top products based on revenue. However, Pfizer has several other drugs that are also well-known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline due to patent loss, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.

It is projected that Pfizer will again be the leading company based on pharmaceutical revenue in 2023, still boosted by high Comirnaty (COVID-19 vaccine) sales. Merck & Co., manufacturer of top drug Keytruda, should increase to second place, according to these projections.

This statistic shows the total revenue of pharmaceutical company AstraZeneca from 2006 to 2024. AstraZeneca plc is one of the top 10 pharmaceutical companies worldwide (based on Rx drug revenue). The multinational company is headquartered in London, UK. AstraZeneca is focused on products for the following major disease areas: cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. Together with the Oxford University, the company also developed one of the first effective COVID-19 vaccines. In 2024, the company's revenue topped ** billion U.S. dollars for the first time.